In addition, a related study found that 88% of patients with recurrent PCa had PSMA-positive (PSMA+) phenotypes, suggesting that most patients with mCRPC may be relatively sensitive and responsive to PSMA-targeted therapy (31). Here, FOLH1 is linked to posterior cortical atrophy.